The global coagulation analyzers/reagents market is expected to reach USD
7.9 billion by 2024, according to a new report by Grand View Research, Inc.
Rising technological advancements in coagulation analyzers are expected to be
the most impact rendering driver for lucrative growth of the market. Automation
is the key development that has occurred in recent years.
The most relevant advancement includes combination of different assay
procedures in single equipment and various commercially available hemostasis
analyzers, which are capable of performing tests such as Prothrombin Time (PT),
Activated Partial Thromboplastin Time (APTT), D-Dimer, and Fibrinogen as well
as these machines can perform chromogenic and immunologic assays.
Moreover, these systems may have the capacity of holding more samples,
providing faster results, and increasing the efficiency of laboratory workflow.
The advancements in hemostasis analyzers are as follows:
·
Integration of
the system with track line systems and work cells, which may improve the
reliability of analysis in terms of single detection system and preanalytical
check for interfering substances
·
Failure
pattern sensors, which detect insufficient sample levels and clots and cap
piercing, which enhances safety and sample integrity
·
Automatic
reflex testing, repeat testing, and redilution
In depth research report on a Coagulation
Analyzer Market
Further key findings from the study suggest:
·
Clinical
laboratory analyzers held over 70.0% of the market share in 2015 and are
predicted to sustain its dominance over the forecast period.
·
Advantages
such as use of whole blood as sample, no pre-analytical delay and requirement
of lesser reagents, further boost growth of Point of Care analyzers.
·
Reagents held
the highest market share in 2015. This dominance may be attributed to
increasing usage of hemostasis analyzers coupled with easy availability of
reagents.
·
Optical
technology based hemostasis analyzers held the largest share in 2015 and is
expected to grow at a CAGR of over 6.0% over the forecast period.
·
The market is
majorly dominated by the prothrombin test. The APTT test is estimated to
account for the second largest share in the market in 2015.
·
Hospitals are
expected to witness lucrative growth over the forecast period. This can be
attributed to high number of hospitals in developing economies.
·
For instance,
Mexico has over 4,500 hospitals and out of these 67.0% hospitals are private
and remaining 33.0% hospitals are public hospitals.
Grand View Research has segmented the global Coagulation Analyzers &
Reagents market on the basis of product, technology, test type, end-use and
region.
Product Outlook (Revenue, USD Million, 2013 -
2024)
·
Analyzers
o
Clinical
Laboratory Analyzers
o
Point of Care
Analyzers
·
Consumables
o
Reagents
o
Stains
Technology Outlook (Revenue, USD Million, 2013
- 2024)
·
Mechanical
·
Electrochemical
·
Optical
o
Photo
optical/Chromogenic/Immuno
o
Others/Nephelometric
·
Others
Test Type Outlook (Revenue, USD Million, 2013
- 2024)
·
APTT
·
D-Dimer
·
Fibrinogen
·
Prothrombin
·
Others
End-Use Outlook (Revenue, USD Million, 2013 -
2024)
·
Hospitals
·
Research
Institutes
·
Diagnostic
Centers
·
Others
Regional Outlook (Revenue, USD Million, 2013 -
2024)
·
North America
o
U.S.
o
Canada
·
Europe
o
UK
o
Germany
·
Asia Pacific
o
Japan
o
China
·
Latin America
o
Brazil
o
Mexico
·
MEA
o
South Africa
Browse more research reports of this category:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting
company, registered in the State of California and headquartered in San
Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, the company offers market intelligence studies ensuring
relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
For more market analysis reports, please
visit: http://www.grandviewresearch.com/
No comments:
Post a Comment